Effect of Bariatric Surgery on Gut Hormones Production and Cure of Type 2 Diabetes Mellitus

Conditions

Surgery

Keywords

Type 2 diabetes mellitus, Y-Roux gastric bypass, Gut hormones, Gene expression, Surgery

Brief summary

Type 2 diabetes mellitus (T2DM) is a relevant public health problem and obesity has been associated as the major risk factor. Roux-en-Y gastric bypass is an effective method to treat severe obesity, and its metabolic benefits can lead to early and complete remission of T2DM, even before a considerable weight loss. We have hypothesized that intestinal anatomic changes may change intestinal genes expression related to glycemic control. The knowledge of mechanisms mediating the glycemic control after Roux-en-Y gastric bypass and it site of action in bowel may eventually help to develop alternative, less invasive and safer surgery for the treatment of T2DM, as well as drug development for the newly targets identified.

Lemos GO, Torrinhas RS, Machado NM, Waitzberg DL.

2025-11-12

10.1002/lipd.70019

Reduced intestinal FADS1 gene expression and plasma omega-3 fatty acids following Roux-en-Y gastric bypass.

Garla P, Sala P, Torrinhas RSM, Machado NM, Fonseca DC, da Silva MM, Ravacci GR, Belarmino G, Ishida RK, Guarda IFMS, de Moura EGH, Sakai P, Santo MA, da Silva IDCG, Pereira CCA, Heymsfield S, Corrêa-Giannella MLC, Calder PC, Waitzberg DL.

2018-05-299 citations

10.1016/j.clnu.2018.05.011

Comparison of Virtual Nutri Plus® and Dietpro 5i® software systems for the assessment of nutrient intake before and after Roux-en-Y gastric bypass.

Silva MM, Sala PC, Cardinelli CS, Torrinhas RS, Waitzberg DL.

2014-11-017 citations

10.6061/clinics/2014(11)02

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

No

Inclusion criteria

Type 2 diabetes mellitus (T2DM) diagnosis Duration of T2DM \>5 years Use of oral antidiabetic agents Body Mass Index \>40 kg/m2 Candidates to Roux-en-Y gastric bypass

Exclusion criteria

Type 1 diabetes mellitus or non-diabetics Use of insulin Thyroid diseases Candidate to other surgery technique Body Mass Index \<40 kg/m2 Presence of bacterium H. Pylori

Design outcomes

Primary

Measure	Time frame	Description
Patient Selection	2013	10 patients fully completed with all biological samples colected in the preoperative and postoperative periods (gastrointestinal tissue). RNA extraction of gastrointestinal samples is being performed.

Countries

Brazil

Outcome results